JPWO2021194879A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021194879A5 JPWO2021194879A5 JP2022557169A JP2022557169A JPWO2021194879A5 JP WO2021194879 A5 JPWO2021194879 A5 JP WO2021194879A5 JP 2022557169 A JP2022557169 A JP 2022557169A JP 2022557169 A JP2022557169 A JP 2022557169A JP WO2021194879 A5 JPWO2021194879 A5 JP WO2021194879A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- pharmaceutical composition
- pharmaceutically acceptable
- lrrk2
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 102000009784 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Human genes 0.000 claims 3
- 108010020246 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Proteins 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 239000012867 bioactive agent Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010024229 Leprosy Diseases 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims 1
- 208000034799 Tauopathies Diseases 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000000973 chemotherapeutic effect Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 230000003959 neuroinflammation Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062992952P | 2020-03-21 | 2020-03-21 | |
| US62/992,952 | 2020-03-21 | ||
| PCT/US2021/023183 WO2021194879A1 (en) | 2020-03-21 | 2021-03-19 | Indazole based compounds and associated methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023518830A JP2023518830A (ja) | 2023-05-08 |
| JPWO2021194879A5 true JPWO2021194879A5 (es) | 2024-03-13 |
Family
ID=75539924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022557169A Pending JP2023518830A (ja) | 2020-03-21 | 2021-03-19 | インダゾール系化合物及び関連使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12053469B2 (es) |
| EP (1) | EP4121422A1 (es) |
| JP (1) | JP2023518830A (es) |
| KR (1) | KR20230004511A (es) |
| CN (1) | CN115697990A (es) |
| AU (1) | AU2021244180A1 (es) |
| BR (1) | BR112022018909A2 (es) |
| CA (1) | CA3172387A1 (es) |
| CO (1) | CO2022014718A2 (es) |
| IL (1) | IL296648A (es) |
| MX (1) | MX2022011674A (es) |
| WO (1) | WO2021194879A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3172387A1 (en) | 2020-03-21 | 2021-09-30 | Arvinas Operations, Inc. | Indazole based compounds and associated methods of use |
| IL305933A (en) | 2021-03-19 | 2023-11-01 | Arvinas Operations Inc | Indazole-based compounds and related methods of use |
| EP4421071A1 (en) * | 2021-10-22 | 2024-08-28 | Gluetacs Therapeutics (Shanghai) Co., Ltd. | Crbn e3 ligase ligand compound, protein degrading agent developed on the basis of ligand compound, and their applications |
| EP4276097A1 (en) | 2022-05-10 | 2023-11-15 | University Of Dundee | Aminopyrimidinyl derivatives for the treament of parkinson's disease |
| WO2024010818A2 (en) * | 2022-07-07 | 2024-01-11 | University Of Tennessee Research Foundation | Proteolysis targeting chimera (protac) of selective androgen receptor degrader (sard) compounds and methods of use thereof |
| WO2024054876A1 (en) * | 2022-09-07 | 2024-03-14 | Arvinas Operations, Inc. | Leucine rich repeat kinase 2 (lrrk2) degrading compounds and associated methods of use |
| WO2024173646A1 (en) * | 2023-02-16 | 2024-08-22 | Innovo Therapeutics, Inc. | Cyclin-dependent kinase degrading compounds |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| JP5713367B2 (ja) * | 2010-06-04 | 2015-05-07 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｌｒｒｋ２モジュレーターとしてのアミノピリミジン誘導体 |
| EP3608317A1 (en) | 2012-01-12 | 2020-02-12 | Yale University | Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase |
| WO2014134776A1 (en) * | 2013-03-04 | 2014-09-12 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
| WO2014134774A1 (en) * | 2013-03-04 | 2014-09-12 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
| US9718818B2 (en) | 2013-08-22 | 2017-08-01 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
| KR20240038809A (ko) | 2014-04-14 | 2024-03-25 | 아비나스 오퍼레이션스, 인코포레이티드 | 단백질분해의 이미드-기초된 조절인자 및 연관된 이용 방법 |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| US20160058872A1 (en) | 2014-04-14 | 2016-03-03 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| US9694084B2 (en) | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| JP7273713B2 (ja) | 2017-02-08 | 2023-05-15 | ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド | ヘテロ二官能性化合物を用いた調整可能な内因性タンパク質分解 |
| IL295603B2 (en) | 2017-09-22 | 2024-03-01 | Kymera Therapeutics Inc | Protein compounds and their uses |
| CN118480030A (zh) | 2018-04-13 | 2024-08-13 | 阿尔维纳斯运营股份有限公司 | 小脑蛋白配体和包括其的双官能化合物 |
| WO2019222173A1 (en) | 2018-05-15 | 2019-11-21 | E-Scape Bio, Inc. | Fused tetrazoles as lrrk2 inhibitors |
| AU2019361964A1 (en) | 2018-10-16 | 2021-03-18 | Dana-Farber Cancer Institute, Inc. | Degraders of wild-type and mutant forms of LRKK2 |
| EP4076536A4 (en) | 2019-12-17 | 2024-05-01 | Kymera Therapeutics, Inc. | IRAQ DEGRADATION AGENTS AND THEIR USES |
| CA3172387A1 (en) | 2020-03-21 | 2021-09-30 | Arvinas Operations, Inc. | Indazole based compounds and associated methods of use |
-
2021
- 2021-03-19 CA CA3172387A patent/CA3172387A1/en active Pending
- 2021-03-19 WO PCT/US2021/023183 patent/WO2021194879A1/en active Application Filing
- 2021-03-19 JP JP2022557169A patent/JP2023518830A/ja active Pending
- 2021-03-19 EP EP21719336.6A patent/EP4121422A1/en active Pending
- 2021-03-19 CN CN202180035521.9A patent/CN115697990A/zh active Pending
- 2021-03-19 BR BR112022018909A patent/BR112022018909A2/pt not_active Application Discontinuation
- 2021-03-19 IL IL296648A patent/IL296648A/en unknown
- 2021-03-19 KR KR1020227036283A patent/KR20230004511A/ko unknown
- 2021-03-19 MX MX2022011674A patent/MX2022011674A/es unknown
- 2021-03-19 AU AU2021244180A patent/AU2021244180A1/en active Pending
- 2021-03-19 US US17/207,325 patent/US12053469B2/en active Active
-
2022
- 2022-10-18 CO CONC2022/0014718A patent/CO2022014718A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2986546B2 (ja) | スマトリプタンを含有する組成物 | |
| JP2020183410A5 (es) | ||
| ES2948805T3 (es) | Composiciones dispersables | |
| JP2020512337A5 (es) | ||
| JP2008540672A (ja) | 病状に起因する性的機能不全の治療方法 | |
| HUP9802339A2 (hu) | Darifenacint tartalmazó gyógyászati készítmények | |
| JP2006516570A5 (es) | ||
| WO2001095912A1 (en) | COMPOSITIONS CONTROLLING RELEASE pH RANGE AND/OR SPEED | |
| CA2527368A1 (en) | Pharmaceutical composition | |
| RU2001119054A (ru) | Калиевая соль (S)-омепразола | |
| JPWO2021194879A5 (es) | ||
| NZ252693A (en) | Use, in the preparation of an anti-ischemic medicament, of [[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]h y drazono]propanedinitrile | |
| CA2411882A1 (en) | Solid valsartan pharmaceutical compositions | |
| JP2003535895A5 (es) | ||
| JP2004532828A5 (es) | ||
| ES2508490T3 (es) | Formulación de trimetazidina con diferentes perfiles de liberación | |
| RU2006115784A (ru) | Применение l-бутилфталида для изготовления лекарственного средства для профилактики и лечения церебрального инфаркта | |
| JP2013544271A5 (es) | ||
| RU2000116269A (ru) | Производные 5-(2-имидазолиниламино) бензимидазола, их получение и применение в качестве агонистов альфа-адренорецепторов с улучшенной метаболической устойчивостью | |
| JP2665357B2 (ja) | 心不全治療用医薬組成物 | |
| KR101282847B1 (ko) | 실로스타졸을 함유하는 고체분산체 및 이를 포함하는 약학 조성물 | |
| JP2006506319A5 (es) | ||
| JP2004525912A5 (es) | ||
| KR101276571B1 (ko) | 4-((4-((4-(2-시아노에텐일)-2,6-디메틸페닐)아미노-2-피리미딘일)아미노)벤조니트릴의 푸마레이트 | |
| JPH10511931A (ja) | 非インシュリン依存性糖尿病の患者において胃空腹を抑制する１，５−ベンゾジアゼピン誘導体の使用 |